IGF1 and metabolic dysfunction-associated steatotic liver disease: In MASLD, chronic insulin resistance, hyperinsulinemia, and elevated IGF-1 signaling promote epithelial proliferation and inhibit apoptosis, contributing to carcinogenesis in both the esophagus and stomach [25].